Madrigal Pharmaceuticals, Inc.

NASDAQ•MDGL

CEO: Mr. William J. Sibold

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2007-02-06

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Contact Information

Four Tower Bridge, Suite 200 200 Barr Harbor Drive, West Conshohocken, PA, 19428, United States

267-824-2827

www.madrigalpharma.com

Market Cap

$10.17B

P/E (TTM)

-34.5

17.2

Dividend Yield

52W High

$615.00

52W Low

$265.00

52W Range

51%

Rank57Top 83.3%

2.4

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 2.4 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$321.08M+0.00%

4-Quarter Trend

EPS

-$2.57+0.00%

4-Quarter Trend

FCF

-$133.07M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Rezdiffra Product Revenue Surge Net product revenue reached $958.4M in 2025, a massive increase from $180.1M in 2024, driven by strong commercial execution.

Global Commercial Launch Progress Launched Rezdiffra in US (April 2024) and Germany (September 2025); secured US patent protection for dosing until February 2045.

Pipeline Expansion Secured Acquired exclusive global licenses for MGL-2086 (GLP-1) and ervogastat (DGAT-2) in 2025, bolstering the focused MASH pipeline.

Strong Cash Position Maintained Cash, cash equivalents, and marketable securities totaled $988.6M as of December 31, 2025, funding operations past one year.

Risk Factors

Sole Product Dependency Risk Business highly dependent on Rezdiffra success; accelerated approval requires confirmatory data from ongoing post-marketing trials.

Continued Operating Losses Expected Accumulated deficit reached $2.090B by year-end 2025; expects to incur additional operating losses while commercializing Rezdiffra.

Competitive Landscape Intensifying Over 140 drugs in development for MASH; competition includes Novo Nordisk's semaglutide, which was approved in the US.

Regulatory Approval Contingency Full US approval contingent on positive outcomes from MAESTRO-NASH OUTCOMES trial, with expected readout in 2027.

Outlook

Maximizing Rezdiffra Commercial Value Targeting quarterly sales annualizing greater than $1.0B by December 31, 2025, leveraging broad first-line payer access.

Expanding Rezdiffra Indication Potential Expect 2027 data readout from OUTCOMES trial to support full approval and potential F4c cirrhosis indication expansion.

Advancing Next-Generation Pipeline Plan to initiate MGL-2086 Phase 1 study in Q2 2026; IND-enabling activities for six siRNA candidates expected to begin in 2026.

Liquidity Funding Strategy Available cash sufficient to fund operations past one year; future needs may require equity/debt financing or strategic partnerships.

Peer Comparison

Revenue (TTM)

BAX

$11.24B

+5.7%

JAZZ

$4.27B

+4.9%

BMRN

$3.22B

+12.9%

Gross Margin (Latest Quarter)

JAZZ

97.9%

-12.3pp

IONS

96.1%

-0.7pp

EXEL

95.6%

+0.1pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
VRNA	$72.68B	-145.1	-30.0%	42.7%
MRNA	$21.30B	-7.5	-30.1%	15.5%
ROIV	$20.25B	-24.4	-18.3%	4.0%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

32.8%

Strong Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

25%

Cash Flow Needs Attention

Deep Research

Next earnings:Apr 29, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data